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Stem cell–mediated tolerance inducing strategies in organ trans-
plantation. The scope of possible tools to modulate the recip-
ients immune response towards tolerance induction basically
includes deletional and non deletional mechanisms, which are
currently targeted by various strategies including monoclonal
antibodies, cytokine deviation, chimerism induction and the
support of regulating T-cells. Here we summarize the main find-
ings in the field derived from experimental animal studies and
currently performed clinical studies. This review focuses to give
a clinically relevant overview over relevant tolerance induc-
ing concepts, taking into consideration risk profiles and clinical
efficacy associated with specific immunosuppressive regiments
currently applied in the clinical setting of transplantation.
Ever since the seminal experiments conducted by
Billingham, Brent, and Medawar [1] there was unequiv-
ocal prove of concept that specific tolerance to a defined
set of donor antigens can be acquired throughout life.
The fact that functional tolerance is not genetically en-
coded on specific genes has been the fundamental sci-
entific bases for a broad spectrum of investigations to
design possible strategies to alter human’s immunologic
response patterns. A major common task of various tol-
erance trials in animal and humans aims at selective ne-
glect of donor-specific defense mechanisms related to
major histocompatibility complex (MHC)–incompatible
organ antigens. Achieving that specific goal of donor-
specific tolerance would not only minimize the risk of
the recipient to suffer from serious side effects resulting
from continuous immunosuppressive therapy but also it
would prevent loss of long-term graft function caused by
chronic rejection processes. Recently, numerous insights
into the dynamic interrelationships of host immune re-
sponses elicited by donor antigen presentation, either on
the graft itself or on specialized antigen-presenting cells
have substantially broadened our understanding of the
cascade of events that result in the acquisition of toler-
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ance. By definition, tolerance can be described in general
terms as a state of unresponsiveness to self or foreign anti-
gens in the absence of immunosuppressive therapy. Infer-
ably, the tolerogenic state to a genetically unrelated organ
must be kept in the context of otherwise unrestricted host
immune competence to any potential threat jeopardizing
the host. In a clinical setting, the benchmark for the es-
tablishment of tolerance induction means complete and
successful withdrawal of immunosuppressive drugs.
There is persuasive clinical evidence that tolerance
can be attained in humans. One important approach to
achieve unresponsiveness to MHC mismatched organs is
the creation of a chimeric state in which large numbers
of donor cells are maintained in the recipient [2, 3].
Allogeneic bone marrow transplantation (BMT) to
recipients with hematologic malignancies has demon-
strated successful tolerance induction in chimeric hosts
who received a second-set kidney from the same donor.
These grafts were tolerated without any immunosup-
pression [2]. In most of these cases, however, these
transplants were done in genotypically human leukocyte
antigen (HLA)-identical donor-recipient combinations.
So far, the use of BMT to induce tolerance to solid or-
gan transplants and cellular grafts from the same living
donor was not considered by transplant physicians since
HLA-identical family donors are available only for a mi-
nority of patients. Even in this “ideal” situation BMT
would have been a maneuver associated with substantial
immediate risk for the recipient and thus was considered
too toxic to perform in organ transplant recipients [4, 5].
However, new developments in the field of hematopoi-
etic transplantation may allow the development of treat-
ment strategies which envisage donor-specific tolerance
induction to donor organs after prior establishment of
stable hematopoietic chimerism [6]. First, lethal graft-
versus-host disease (GVHD) can now regularly be
overcome by the use of megadoses of granulocyte-colony-
stimulating factor (G-CSF) mobilized peripheral blood
progenitor stem cell grafts after vigorous T-cell depletion
[7, 8]. Another major achievement is the establishment
of nonmyeloablative but highly immunosuppressive con-
ditioning regimens for hematopoietic transplantation.
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This modality often called “minitransplant” procedure
is used with increasing frequency for patients with hema-
tologic malignancies who bear a highly increased risk of
toxicity after BMT or peripheral blood progenitor cell
transplantation (PBPCT), respectively [9–11]. However,
before nonmyeloablative preparatory regimens can be
used as conditioning regimens for organ transplants in
general, two major obstacles have to be resolved. First,
for the time being, there is no reduced conditioning regi-
men which can reliably induce stable chimerism in any of
all the possible donor/recipient MHC combinations. Clin-
ical trials to induce mixed chimerism following less toxic
nonmyeloablative regimens in the non-HLA identical
setting have first begun [11, 12]. Second, the potential
risk of GVHD after second set organ transplantation
of lymphocyte-rich organs, such as small bowel or lung
grafts, has not been tested clinically.
Recently, a preconditioning strategy including an-
tithymocyte globulin (ATG), total lymphoid irradiation
and simultaneous administration of CD34+ (stem cell)-
enriched donor peripheral blood mononucuclear cells
was tested on a background of cyclosporine A (CSA)
and prednisone in MHC-mismatched living donor re-
nal transplantation [3]. Mixed chimerism (simultaneous
coexistence of donor and recipient derived hematopoi-
etic cells within the same host) was achieved in three
of four patients while no clinical signs of GVHD were
observed. Two of four patients could be weaned success-
fully from immunosuppressive medication but eventu-
ally had to be reversed by antirejection therapy due to
acute rejection episodes [abstract; Millan MT et al, Trans-
plantation 74:37, 2002]. Still a matter of debate remains
the question whether the induction of macrochimerism
(defined as more than 5% donor-derived hematopoi-
etic cells within the peripheral blood compartment)
has to be established long-term or whether a transient
state of “macrochimerization” will be sufficient to main-
tain self-perpetuating tolerogenic responses in the host’s
own immunologic repertoire. Possible underlying mech-
anisms include the generation of regulatory T cells upon
exposure of developing thymocytes to donor antigens
presented by bone marrow derived antigen-presenting
cells (APC) within the thymus [13] or, alternatively, ex-
trathymic deletion of mature T cells following bone mar-
row transplantation [14]. Presumingly, deletional and
nondeletional mechanisms must synergize to induce and
maintain a tolerogenic state, respectively. In order to
delineate how peripheral T cells are rendered nonre-
sponsive to donor bone marrow various experimental
models have been set up to investigate defined immuno-
logic mechanisms such as anergy related to costimulatory
blockade [15], immune deviation [16], suppression [17],
and apoptosis [18, 19]. Successful deletion of allospecific
cytotoxic T lymphocytes was achieved in a mouse model
and involved concomitant application of anti-CD40L an-
tibody (MR1) and CTLA-4-Ig fusion protein together
with donor BMT [14, 20]. Noteworthy, using this proto-
col CD4+ T cells are deleted progressingly over time and
both passive cell death (PCD) and activation–induced
cell death (AICD) contributed to eliminate these cells
[21]. Apoptosis by passive cell death is assumed to be me-
diated by “death of neglect” consequently the result of
nonstimulation related to lack of survival signals (antigen
stimulation, costimulatory molecules, cytokines) whereas
AICD is defined as active deliver of proapoptotic signals
to T cells, for instance fas (CD95 (reviewed in [22]). As
far as tolerance is induced via establishment of mixed
chimerism, there is clear evidence that deletion of donor
reactive T cells is a crucial element during the process of
tolerance development [23]. Noteworthy, the authors of
this paper clearly demonstrated that simultaneous admin-
istration of CSA together with anti-CD40L monoclonal
antibody did not break the tolerogenic potential of this
costimulatory blockade regimen, an important piece of
knowledge for potential clinical trials. Still, a matter of
debate arises around the question whether tolerance can
be considered stable and robust if the chimeric state of
the host is only transient. From the clinical point of view
results are still confounding.
Along this line of thinking, rat animal experiments of
our own showed that a unique population of macrophages
isolated from the peritoneal cavity possesses the abil-
ity to down-regulate donor-specific alloreactivity in a
model of heterotopic heart transplantation in the Lewis
to Darby inbred rat strain combination [24]. Precondi-
tioning of allogeneic hosts with donor-derived peritoneal
macrophages, expanded in vitro with macrophage-
colony-stimulating factor (M-CSF) for 5 days, 7 days
before performing a second-set heart transplantation, in-
duced long-term graft acceptance in conjunction with
transient mixed chimerism. These results are in line with
findings using rat embryonic stem cell-like cells (RESC)
which, upon injection into the portal vein of nonimmuno-
suppressed allogeneic host rats, were able to prevent al-
lospecific rejection of their own [25]. In turn, these cells
gave rise to macrophages and B cells which seeded the
thymus and lymphatic host tissues, hereby setting the ba-
sis for antigen-specific down-regulation of alloreactive
T cells, as demonstrated in vitro when testing mixed lym-
phocyte proliferation responses to donor and third-party
stimulator cells. Second-set heart grafts were accepted
long-term after preconditioning host animals intrapor-
tally with 106 RESC. These findings are in line with cur-
rent knowledge about fetal blood cells circulating in the
mother’s peripheral blood compartment, where they can
be detected and explored for prenatal genetic analysis
[26]. At current state, the characterization of the spe-
cific subset of M-CSF–stimulated monocytes endowed
with the unique tolerogenic potential aforementioned
has revealed a capacity to induce regulatory T cells when
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cocultured for 2 to 4 days in the presence of allogeneic
T lymphocytes. Direct cocultered CD4+ T cells (but not
T cells cocultured in separate chambers thus withhold-
ing direct physical interaction with adherent monocytes)
coexpressed CD25+ and up-regulated the transcription
level of Foxp3, which is considered an important candi-
date gene for regulatory T cells [27]. When tested in vitro
after exposure to M-CSF–treated macrophages, these
newly generated CD4+/CD25+ T cells were able to sub-
stantially suppress allogeneic T lymphocyte proliferation
in mixed lymphocyte cultures in a donor-specific fashion
(unpublished data). We surmise that there is a specific
subset of macrophages which, upon appropriate in vitro
modification, can be used in vivo to create a transient state
of mixed chimerism by deleting alloreactive cytotoxic T
lymphocytes and upon homing to secondary lymphatic
tissues are able to expand the pool of donor-specific T
regulatory cells.
In summary, stem cell–related tolerance induction can
either be achieved, at least in small animals,via stable in-
duction of mixed chimerism in conjunction with appropri-
ate costimulatory blockade regimens, or alternatively, be
designing donor-derived antigen-presenting cells which
will not only deviate direct cytotoxic T cell attack but
also shape the host’s own regulatory T cell repertoire to
take over the selective tolerogenic potential transmitted
by specialized donor APCs of monocytic origin. Prospec-
tive clinical protocols are conducted at current state to
investigate these assumptions in a first cadaveric kidney
transplantation trial.
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